MC

437.65

-1.71%↓

SANES

6.869

-0.61%↓

ALV

339.9

+0.03%↑

BNP

75.45

+0.33%↑

BBVA

12.755

+0.08%↑

MC

437.65

-1.71%↓

SANES

6.869

-0.61%↓

ALV

339.9

+0.03%↑

BNP

75.45

+0.33%↑

BBVA

12.755

+0.08%↑

MC

437.65

-1.71%↓

SANES

6.869

-0.61%↓

ALV

339.9

+0.03%↑

BNP

75.45

+0.33%↑

BBVA

12.755

+0.08%↑

MC

437.65

-1.71%↓

SANES

6.869

-0.61%↓

ALV

339.9

+0.03%↑

BNP

75.45

+0.33%↑

BBVA

12.755

+0.08%↑

MC

437.65

-1.71%↓

SANES

6.869

-0.61%↓

ALV

339.9

+0.03%↑

BNP

75.45

+0.33%↑

BBVA

12.755

+0.08%↑

Search

Sartorius Stedim Biotech.

Closed

SectorFinance

203.9 2.46

Overview

Share price change

24h

Current

Min

199.05

Max

208.4

Key metrics

By Trading Economics

Income

75M

115M

Sales

-6.7M

745M

P/E

Sector Avg

92.346

24.617

EPS

1.16

Dividend yield

0.34

Profit margin

15.498

Employees

9,961

EBITDA

124M

256M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.75% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.34%

4.23%

Next Earnings

22 Jul 2025

Market Stats

By TradingEconomics

Market Cap

2.4B

19B

Previous open

201.44

Previous close

203.9

News Sentiment

By Acuity

39%

61%

141 / 538 Finance

Technical Score

By Trading Central

Confidence

Bullish Evidence

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

26 Jun 2025, 23:49 UTC

Earnings

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 Jun 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 Jun 2025, 21:30 UTC

Earnings

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 Jun 2025, 21:07 UTC

Earnings

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 Jun 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 Jun 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 Jun 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 Jun 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 Jun 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 Jun 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 Jun 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 Jun 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 Jun 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 Jun 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 Jun 2025, 23:19 UTC

Acquisitions, Mergers, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 Jun 2025, 22:06 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 Jun 2025, 21:15 UTC

Earnings

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 Jun 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 Jun 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 Jun 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 Jun 2025, 21:07 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 Jun 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 Jun 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 Jun 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 Jun 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 Jun 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 Jun 2025, 20:52 UTC

Earnings

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 Jun 2025, 20:51 UTC

Earnings

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 Jun 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

17.75% upside

12 Months Forecast

Average 234.67 EUR  17.75%

High 250 EUR

Low 210 EUR

Based on 9 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

5

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

202.7 / 211.7Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

141 / 538 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.